Fig. 5: IFITM3 is prognostic in newly diagnosed AML patients and a potential dependency in AML cells.

A Correlation of IFNγ signaling score with gene expressions in the single cell data. Genes in red have a positive correlation and genes in blue have a negative correlation. B Correlation of IFITM3 expression with IFNγ signaling score at an individual patient level. Error band represents 95% confidence interval. T test was used to evaluate the significance of Pearson correlation. C IFITM3 expression in AML blasts was assessed by flow cytometry after a 24-h stimulation with 10 ng/ml IFNγ. Data represents results from 2 patients’ CD14+ blasts and 2 patients’ CD34+ blasts, with each condition having 3 replicates. The error showed standard error of mean. Two-sided t test was used. D Kaplan-Meier survival curve of the AML patients from TCGA, Beat-AML and MDACC by median IFITM3 expression in the bulk RNA profiling data. E UMAP projection of all patients’ cells scored by IFITM3 expression in cells. F Change in cell line fitness following genetic deletion of IFITM3 in the DepMap CRISPR knockout screen data, showing results in the 26 AML cell lines tested. G Representative multiplex IF panel. Baseline AML sample with CD34 positive blasts show low amounts of IFITM3(Top). Post relapse AML sample with CD34 positive blasts show high amounts of IFITM3 (Bottom). Green is CD34, red is IFITM3, blue is DAPI. Scale bar 50 μm. The experiment was repeated 2 times. H Density plot of IFITM3 fluorescence intensity on AML blasts at diagnosis and post relapse. I Violin plot of fluorescence intensity on AML blasts at diagnosis and post relapse. Post relapse AML sample show significantly higher amounts of IFITM3. Two-sided Wilcoxon test was used. Source data are provided as a Source Data file.